Aroa Biosurgery signs exclusive U.S. co-promotion deal for Endoform
Aroa Biosurgery has agreed an exclusive U.S. co-promotion deal with Mölnlycke Healthcare US. FY27 revenue and EBITDA guidance is unchanged, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Aroa Biosurgery Limited has signed an exclusive agreement with Mölnlycke Healthcare US to co-promote its Endoform product in U.S. post-acute care settings. The agreement takes effect on October 16, 2026, according to TradingView, which cited the company's announcement.
Aroa will keep ownership of the product and control over manufacturing under the deal. The company also said its FY27 guidance stands: revenue of NZ$115 million to NZ$125 million and EBITDA of NZ$8 million to NZ$11 million.
why it matters
The deal widens distribution for a small medical device maker without changing its financial outlook, so the direct effect on ARX shares is likely to be limited. Any further move will depend on how quickly the partnership lifts Endoform sales.
tags
instruments
sources
- Aroa Biosurgery Limited (ARX) Inks Exclusive U.S. Co-Promotion for Endoform — TradingView, 21 October 2026 at 00:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗